<DOC>
	<DOC>NCT00550173</DOC>
	<brief_summary>The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in patients who have never smoked and have locally advanced or metastatic Nonsquamous Non-Small Cell Lung Cancer who have failed a first-line chemotherapy treatment.</brief_summary>
	<brief_title>A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients with locally advanced or metastatic nonsquamous nonsmall cell lung cancer Patients must be nonsmokers Patients must have at least one measurable lesion Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease. Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication Patients who have previously received treatment with drugs against the human epidermal growth factor receptors Patients who have previously received treatment with drugs which have similar targets as Pemetrexed Patients who have any known significant ophthalmologic abnormalities of the surface of the eye Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>